FDA 483 OBSERVATION · #1070 OF 1,932 MOST-CITED
Conflict of interest
FDA cited this observation 15 times across 15 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
How FDA worded it — real examples
The IRB allowed a member to participate in the IRB's continuing review of a project in which the member had a conflicting interest.
The IRB allowed a member to participate in the IRB's continuing review of a project in which the member had a conflicting interest.
The IRB allowed a member to participate in the IRB's initial of a project in which the member had a conflicting interest.
The IRB allowed a member to participate in the IRB's initial and continuing review of a project in which the member had a conflicting interest.
The IRB allowed a member to participate in the IRB's initial of a project in which the member had a conflicting interest.
The IRB allowed a member to participate in the IRB's initial and continuing review of a project in which the member had a conflicting interest.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →